These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11368253)

  • 1. Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
    Martin RM; Shakir S
    Drug Saf; 2001; 24(6):475-81. PubMed ID: 11368253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.
    Martin RM; Dunn NR; Freemantle SN; Mann RD
    Thorax; 1998 Jul; 53(7):558-62. PubMed ID: 9797754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.
    Mann RD; Kubota K; Pearce G; Wilton L
    J Clin Epidemiol; 1996 Feb; 49(2):247-50. PubMed ID: 8606326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
    Chan J; Hui RL; Spence MM
    J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of prescription event monitoring study of salmeterol.
    Mann RD
    BMJ; 1994 Oct; 309(6960):1018. PubMed ID: 7950701
    [No Abstract]   [Full Text] [Related]  

  • 6. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
    Nelson HS; Weiss ST; Bleecker ER; Yancey SW; Dorinsky PM;
    Chest; 2006 Jan; 129(1):15-26. PubMed ID: 16424409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
    Perrio MJ; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(8):681-95. PubMed ID: 17696581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchodilator treatment in asthma. Increase in deaths during salmeterol treatment unexplained.
    Sears MR; Taylor DR
    BMJ; 1993 Jun; 306(6892):1610-1. PubMed ID: 8101115
    [No Abstract]   [Full Text] [Related]  

  • 9. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK.
    Meier CR; Jick H
    Thorax; 1997 Jul; 52(7):612-7. PubMed ID: 9246132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case-control study of salmeterol and near-fatal attacks of asthma.
    Williams C; Crossland L; Finnerty J; Crane J; Holgate S; Pearce N; Beasley R
    Thorax; 1998 Jan; 53(1):7-13. PubMed ID: 9577515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchodilator treatment in asthma. Study too small to detect increase in deaths.
    Bunney R
    BMJ; 1993 Jun; 306(6892):1610; author reply 1611. PubMed ID: 8101118
    [No Abstract]   [Full Text] [Related]  

  • 14. From adrenaline to formoterol: advances in beta-agonist therapy in the treatment of asthma.
    Campbell LM
    Int J Clin Pract; 2002 Dec; 56(10):783-90. PubMed ID: 12510953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bronchodilator treatment in asthma. Manufacturers underestimate mortality from asthma.
    Inman WH
    BMJ; 1993 Jun; 306(6892):1610; author reply 1611. PubMed ID: 8101116
    [No Abstract]   [Full Text] [Related]  

  • 16. Change in β
    Lietzén R; Virtanen P; Kivimäki M; Korkeila J; Suominen S; Sillanmäki L; Koskenvuo M; Vahtera J
    J Psychosom Res; 2017 Sep; 100():46-52. PubMed ID: 28789792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchodilator treatment in asthma. Regular treatment with beta agonists remains unevaluated.
    Crompton GK
    BMJ; 1993 Jun; 306(6892):1610; author reply 1611. PubMed ID: 8101117
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol.
    Lanes SF; Lanza LL; Wentworth CE
    Am J Respir Crit Care Med; 1998 Sep; 158(3):857-61. PubMed ID: 9731017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
    Nelson HS; Nathan RA; Kalberg C; Yancey SW; Rickard KA
    MedGenMed; 2001 Jul; 3(4):3. PubMed ID: 11549982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A word of caution regarding a new long-acting bronchodilator.
    Bone RC
    JAMA; 1994 May; 271(18):1447-8. PubMed ID: 7909854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.